Abstract
Sirs: Since the first human case description in 2005, the CoreValve self-expanding valve prosthesis (Medtronic, Minneapolis, Minnesota) is available for interventional treatment of aortic valve stenosis in patients with high surgical risk [1]. In the last years, an increasing number of patients treated with transcatheter valve implantation (TAVI). We present a case of Staphylococcus lugdunensis prosthetic valve endocarditis of the CoreValve ReValving
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
